OTCMKTS:CNBX CNBX Pharmaceuticals - CNBX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CNBX Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.53 -0.07 (-11.76%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.53▼$0.5550-Day Range$0.53▼$4.0052-Week Range$0.53▼$12.42Volume5,812 shsAverage Volume11,769 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsFinancialsHeadlinesSEC FilingsShort Interest About CNBX Pharmaceuticals (OTCMKTS:CNBX) StockCNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it develops Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. CNBX Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.Read More Receive CNBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CNBX Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CNBX Stock News HeadlinesNovember 8, 2022 | benzinga.comCNBX Acquires A Controlling Interest In Cancer Immunotherapy DeveloperNovember 8, 2022 | finance.yahoo.comCNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza BiopharmaJanuary 29, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.October 18, 2022 | finance.yahoo.comCNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer TherapyOctober 13, 2022 | finance.yahoo.comCNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and IsraelSeptember 28, 2022 | finance.yahoo.comCNBX Pharmaceuticals Announces New Patent Granted in AustraliaSeptember 12, 2022 | reuters.comCNBX Pharmaceuticals IncAugust 16, 2022 | ca.finance.yahoo.comCNBX Pharmaceuticals Inc. (CNBX)January 29, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…June 10, 2022 | benzinga.comCNBX Pharmaceuticals (OTC:CNBXD), Earnings Estimates, EPS, and RevenueJune 10, 2022 | benzinga.comCNBX Pharmaceuticals (OTC:CNBXD), Analyst Ratings, Price Targets, PredictionsJune 7, 2022 | finance.yahoo.comCNBX Pharmaceuticals Inc. (CNBXD)May 31, 2022 | finance.yahoo.comCNBX Pharmaceuticals Release a New Corporate PresentationMay 14, 2022 | barrons.comCNBX Pharmaceuticals Inc.May 5, 2022 | seekingalpha.comCNBX pharma granted patent in Hong Kong for cancer therapyMay 5, 2022 | finance.yahoo.comCNBX Pharmaceuticals Granted Patent in Hong KongApril 4, 2022 | msn.comNovartis to save at least $1 billion by 2024 thanks to simplified structureApril 4, 2022 | msn.comVertex Pharma sees positive results in Phase 2 trials of new non-opioid pain killerApril 4, 2022 | cnbc.comWhat to watch today: Wall Street looks higher; Twitter soars on Elon Musk stakeApril 4, 2022 | msn.comStocks making the biggest moves in the premarket: Twitter, Tesla, Starbucks and moreApril 1, 2022 | cnbc.comCNBC Transcript: Johnson & Johnson CEO Joaquin Duato Speaks with CNBC’s Meg Tirrell Live During CNBC’s Healthy Returns Summit TodayApril 1, 2022 | cnbc.comWhat to watch today: Wall Street set to wrap up strong month but weak quarterApril 1, 2022 | msn.comStocks making the biggest moves premarket: Walgreens, Baidu, Novavax and othersApril 1, 2022 | msn.comVertex Pharmaceuticals reports positive data on non-opioid pain medicineMarch 28, 2022 | finance.yahoo.comCannabics Pharmaceuticals Changes Name to CNBX PharmaceuticalsNovember 30, 2021 | benzinga.comAvicanna To Bring Its Cannabinoid-Based Drugs To Argentina Via 'Established' Pharma PartnerNovember 4, 2021 | finance.yahoo.comCNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical TrialsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CNBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CNBX Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Biotechnology Sub-IndustryCannabis SectorMedical Current SymbolOTCMKTS:CNBX CUSIPN/A CIK1343009 Webwww.cannabics.com Phone(877) 424-2429FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Key ExecutivesMr. Gabriel Yariv (Age 47)Pres, COO & Exec. Chairman Comp: $261.93kMr. Eyal Barad (Age 58)Co-Founder, CEO & Director Comp: $269.15kMr. Uri Ben-Or CPA (Age 53)CPA, M.B.A., MBA, Chief Financial Officer Comp: $75.32kDr. Sanja Goldberg (Age 47)Chief Technology Officer Comp: $48.12kNoam PermontVP of PR & Investor RelationsDr. Sigalit Ariely-Portnoy Ph.D. (Age 59)Sr. Advisor of Regulation, Validation & Quality and Member of Advisory Board Dr. Tal Mofkadi Ph.D.Financial Advisor & Member of Advisory BoardMr. Yasha Borstein (Age 60)Chief Data Officer Dr. Yaakov Waksman (Age 71)Head of Cannabidiol Research Dr. Ilya Reznik M.D.Head of Neuropsychiatry Devel.More ExecutivesKey CompetitorsGB SciencesOTCMKTS:GBLXMedican EnterprisesOTCMKTS:MDCN3SBioOTCMKTS:TRSBFAbattis BioceuticalsOTCMKTS:ATTBFAbcamOTCMKTS:ABCZFView All Competitors CNBX Stock - Frequently Asked Questions How have CNBX shares performed in 2023? CNBX Pharmaceuticals' stock was trading at $1.86 at the start of the year. Since then, CNBX stock has decreased by 71.8% and is now trading at $0.5251. View the best growth stocks for 2023 here. When did CNBX Pharmaceuticals' stock split? CNBX Pharmaceuticals shares reverse split on Thursday, May 12th 2022. The 1-120 reverse split was announced on Thursday, May 12th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 12th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of CNBX Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other CNBX Pharmaceuticals investors own include Gran Tierra Energy (GTE), Organigram (OGI), KushCo (KSHB), Pennsylvania Real Estate Investment Trust (PEI), Medical Marijuana (MJNA), Auxly Cannabis Group (CBWTF), American Cannabis (AMMJ), GreenGro Technologies (GRNH), MassRoots (MSRT) and Surna (SRNA). What is CNBX Pharmaceuticals' stock symbol? CNBX Pharmaceuticals trades on the OTCMKTS under the ticker symbol "CNBX." How do I buy shares of CNBX Pharmaceuticals? Shares of CNBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CNBX Pharmaceuticals' stock price today? One share of CNBX stock can currently be purchased for approximately $0.53. How can I contact CNBX Pharmaceuticals? CNBX Pharmaceuticals' mailing address is #3 Bethesda Metro Center, Suite 700, BETHESDA, MD 20814, United States. The official website for the company is www.cannabics.com. The company can be reached via phone at (877) 424-2429. This page (OTCMKTS:CNBX) was last updated on 1/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.